Stewart Lyman is Owner and Manager of Lyman BioPharma Consulting LLC in Seattle. He provides advice to biotechnology and pharmaceutical companies as well as academic researchers and venture capital firms. Previously, he spent 14 years as a scientist at Immunex prior to its acquisition by Amgen.
Several years ago, I wrote an article venting my frustrations with having to sift through the fog and jargon of poorly written analyses of the biotech/pharmaceutical industry. I recounted that, “... Read more »
Many rare book collectors keep an eye out for an original copy of Seduction of the Innocent, a cause célèbre when it was published back in the 1950s by psychiatrist... Read more »
Biopharma employees read, as you might expect, a wide spectrum of scientific journals and trade publications. What might be surprising is that their reading lists appear to have expanded recently to... Read more »
Whac-A-Mole, for those of you who are not familiar with it, is a fast-paced arcade game in which mechanical moles pop quickly in and out of holes on a large board.... Read more »
I originally thought about titling this piece “Life Sciences, Biosciences, BioPharma, Biotech, and Healthcare: What’s the Difference?” but that was simply too unwieldy. Many people use these terms interchangeably without... Read more »
Patients ask doctors
Can you sequence my genome?
Enter brave new world
One word description
Newly approved cancer drugs
Unaffordable
Hot biotech trend
Virtual drug companies
Who will do... Read more »
One of the most widely read college textbooks in the 1960s and ‘70s was How to Lie with Statistics by Darrell Huff. Despite the humorous title, the serious intent of... Read more »
More than a 150 years ago Charles Dickens’ A Christmas Carol introduced the character Ebenezer Scrooge, who was the embodiment of greed, “tight-fisted…. a squeezing, wrenching, grasping, scraping,... Read more »
I’m ready to confess that I’ve been basking in a particular drug-induced fantasy for a number of years. It’s a different type than we usual read about, and I suspect... Read more »
Residents of Washington State are currently being buried in an avalanche of ads regarding a citizen’s initiative that would require the labeling of genetically engineered foods sold in grocery stores. Estimates... Read more »
Biopharmaceutical companies are under a great deal of financial pressure these days, and many are tinkering with long established business models. There can be no doubt that the industry is... Read more »
Many fields of endeavor have their own special words, abbreviations, and coded language. People working in each of these disciplines learn over time how to use certain phrases that describe... Read more »
This may seem like a surprising observation, but it’s true. Biopharma companies and baseball teams employ similar strategies that they hope will result in either a blockbuster drug or winning... Read more »
There’s been an awful lot of turnover lately among Big Biopharma R&D chiefs, with departures from Merck, Amgen, Bristol-Myers Squibb, AstraZeneca, Roche, and AbbVie. Their... Read more »
While my primary focus is on the research side of the business, I have to admit that for many biotechs, their survival may be tied to the art of the... Read more »
As a politician, one of the worst things you can be accused of is being a flip-flopper, a person who changes their mind on one or more issues. Another way of... Read more »
Academy Award season is upon us, with the Oscars being polished up in anticipation of the big night. Who knows which Hollywood heavyweights and newcomers will be recognized for their... Read more »
That’s right. I hate to be the bearer of bad news, but there are no apps for treating Parkinson’s either. Or ALS. Or Alzheimer’s, or one of a large number... Read more »
I’ve spent some time over the past few months reading about an American political figure’s transformative role in our health care system. His crusade began when his staff surveyed drug... Read more »
“Observe due measure, for right timing is in all things the most important factor.”
The Greek poet Hesiod wasn’t referring to the drug development process when he wrote... Read more »
Sponsored · Whitepaper
How a patient-centric, technology-driven approach can broaden access to research and reach patients regardless of geography, ethnicity, sex, or gender
PRA Health Sciences
Xconomy Insight · Special Report
Industry experts explain what it takes to launch a new biotech company
From Our Editors · Special Report
Becoming the Cell & Gene Therapy Hub
© 2007-2021, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.
